INTRODUCTION: Continuous femoral nerve blocks for total knee arthroplasty can cause motor @entity425 and thus prevent early mobilisation. Perioperative falls may result as an iatrogenic complication. In this randomised and blinded trial, we tested the hypothesis that a continuous adductor canal block is superior to continuous femoral @entity616 regarding mobilisation ('timed up-and-go' test and other tests) after total knee arthroplasty under general anaesthesia. METHODS: In our study, we included @entity1 scheduled for unilateral knee arthroplasty under general anaesthesia into a blinded and randomised trial. @entity1 were allocated to a continuous adductor canal block (CACB) or a continuous femoral @entity616 (CFNB) for three postoperative days ( @entity773 -3); with a bolus of 15  ml @entity1342 0.375  %, followed by continuous infusion of @entity1342 0.2  % and @entity1 -controlled bolus administration. Both groups received an additional continuous sciatic @entity616 as well as a multimodal systemic analgesic treatment. The primary outcome parameter was mobilisation capability, assessed by 'timed up-and-go' (TUG) test. Analgesic quality, need for opioid rescue and local anaesthetic consumption were also assessed. RESULTS: Forty-two @entity1 were included and analysed (21 @entity1 per group). No significant difference was noted in respect to mobilisation at POD 3 (TUG [s]: CACB 45, CFNB 51). It is worth saying that @entity158 scores (numeric rating scale, NRS) were similar in both groups at POD 3 {rest [median (interquartile range)]: CACB 0 (0-3), CFNB 1 (0-3); stress: CACB 4 (2-5), CFNB 3 (2-4)}. CONCLUSIONS: Concerning the mobilisation capability, we did not actually observe a superior effect of CACB compared with CFNB technique in our @entity1 following total knee arthroplasty. Moreover, no difference was observed concerning analgesia quality.

Continuous adductor canal block versus continuous femoral @entity616 after total knee arthroplasty for mobilisation capability and XXXX treatment: a randomised and blinded clinical trial.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity773 :: ('79585', 'Gene') :: ['POD 1'] @entity425 :: ('MESH:D018908', 'Disease') :: ['weakness of the quadriceps muscle'] @entity1342 :: ('MESH:C037663', 'Chemical') :: ['ropivacaine'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity616 :: ('MESH:D006327', 'Disease') :: ['nerve block']
@entity158 :: (MESH:D010146,Disease) :: ['pain']
